Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced a collaboration with TIME to launch the branded Healthcare Champion of the Year award, honoring U.S. healthcare professionals whose care, innovation and grit are advancing patient care and health systems.
Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026 via the company’s website. Eligible nominees include a wide range of healthcare professionals actively involved in clinical care or care delivery in the U.S., at any career stage, who demonstrate real-world impact aligned to core themes of grit, innovation or patient care. The honoree will be announced ahead of TIME’s “A Year in TIME” celebration on December 9, 2026 in New York City. Johnson & Johnson links this initiative to its broader J&J CareCommunity platform and its long-standing commitment to supporting nurses, community health workers and the global health workforce.
DePuy Synthes (NYSE:JNJ) announced the acquisition of Expanding Innovations, a commercial-stage medical technology company specializing in expandable implant technologies for spine surgery. The deal is intended to strengthen DePuy Synthes’ Spine portfolio and expand its position in the rapidly growing expandable interbody cage market.
Expanding Innovations’ proprietary, non-screw-based interbody cage technology is designed to help reduce post-operative cage collapse and vertebral body subsidence while supporting procedural efficiency and implant stability. Its X-PAC portfolio includes TLIF and LLIF expandable cages and the N-GAGE Lumbar Plate System, with planned expansion into next-generation TLIF/LLIF cages, enhanced instrumentation, and future ALIF solutions. According to DePuy Synthes, Expanding Innovations’ technology will complement the TriALTIS Spine System and be integrated into the VELYS Enabling Tech portfolio for Spine.
Johnson & Johnson (NYSE: JNJ) declared a third-quarter 2026 cash dividend of $1.34 per share on its common stock.
The dividend is payable on September 8, 2026 to shareholders of record and with an ex-dividend date of August 25, 2026.
Johnson & Johnson (NYSE: JNJ) reported Q2 2026 sales of $25.3 billion, up 6.6% year over year, with operational growth of 5.6% and adjusted operational growth of 5.7%. Net earnings were $5.53 billion and diluted EPS was $2.27, both slightly below prior year, while adjusted EPS rose to $2.90, up 4.7%.
Innovative Medicine sales reached $16.38 billion (7.8% reported growth) and MedTech $8.93 billion (4.5% reported growth). Free cash flow year‑to‑date was about $8.7 billion versus $6.21 billion in 2025. The company raised 2026 guidance to estimated reported sales of $100.8–$101.4 billion (7.0–7.6% growth; $101.1 billion midpoint) and adjusted EPS of $11.60–$11.75 (8.2% midpoint growth).
According to Johnson & Johnson, growth was driven by key oncology, immunology and neuroscience products, partially offset by STELARA and other legacy brands. The quarter also included multiple FDA and CE approvals, positive clinical data across several late‑stage assets, and agreements to acquire Firefly Bio and other technologies.
Johnson & Johnson (NYSE: JNJ) received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform, a catheter ablation solution delivering both radiofrequency and pulsed field energy through a single catheter.
Integrated with the CARTO ecosystem, U.S. procedures are expected to begin this summer via a phased commercial rollout.
Johnson & Johnson (NYSE: JNJ) reported new Phase 3 Vivacity-MG3 analyses of IMAAVY (nipocalimab) in antibody-positive generalized myasthenia gravis (gMG) at EAN 2026.
Data show greater MG-ADL improvements vs placebo in early-diagnosed and lower-symptom patients, maintained control after common infections, a safety profile with 84% AEs and fewer SAEs vs placebo, and launch of the PETUNIA pregnancy outcomes study.
Johnson & Johnson (NYSE: JNJ) will invest more than $1 billion to expand its U.S. Vision manufacturing, packaging, and distribution operations in Jacksonville, Florida.
The project includes a new state-of-the-art distribution facility, targets full operation in 2028, supports 3,500 employees, and contributes to a $6 billion annual economic impact in Florida.
Johnson & Johnson (NYSE:JNJ) reported positive Phase 3 MonumenTAL-3 results for TALVEY® plus DARZALEX FASPRO® with or without pomalidomide in relapsed/refractory multiple myeloma.
The combinations cut risk of progression or death by up to 72%, showed 24‑month PFS up to 81.3% and OS up to 89.2%, with safety profiles consistent with monotherapies. Johnson & Johnson has submitted an sBLA to the FDA and a Type II variation to the EMA.
Johnson & Johnson (NYSE: JNJ) is expanding U.S. availability of its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The lens addresses cataract-related vision loss and presbyopia in one procedure and is the first and only U.S. FDA‑approved EDOF IOL without a contrast sensitivity loss warning.
According to Johnson & Johnson, more than 500,000 eyes worldwide have received TECNIS PureSee IOL, 97% of patients would recommend it, and 97% reported no very bothersome visual disturbances. A new patient lifestyle quiz supports pre-surgery decision-making during Cataract Awareness Month.
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase 2/3 ENERGY data for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, a disease with no FDA-approved therapies. The 30 mg/kg group achieved statistically significant durable hemoglobin response and about three times more responders than placebo by 24 weeks.
Mean hemoglobin rose ≥1 g/dL by Week 1, nearly two-thirds met stringent hemoglobin targets by Week 24, fatigue and corticosteroid use improved, safety matched the existing profile, and the sBLA has FDA Priority Review.